IL6 and type 2 diabetes mellitus: As for empagliflozin, this treatment did not significantly alter IL-6 levels in subjects with T2DM [244], although a distinct trial in patients with T2DM with reduced ejection fraction (HFrEF) reported a significant decrease [245].